Clozapine withdrawal emergent dystonias and dyskinesias: A case series

被引:81
作者
Ahmed, S
Chengappa, KNR
Naidu, VR
Baker, RW
Parepally, H
Schooler, NR
机构
[1] Univ Pittsburgh, Med Ctr, Sch Med, Western Psychiat Inst & Clin, Pittsburgh, PA USA
[2] Mayview State Hosp, Special Studies Ctr, Bridgeville, PA USA
[3] Vet Affairs Med Ctr, Pittsburgh, PA USA
[4] Univ Mississippi, Med Ctr, Dept Psychiat & Human Behav, Jackson, MS 39216 USA
关键词
D O I
10.4088/JCP.v59n0906
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Severe psychotic decompensation during clozapine withdrawal has been reported previously. Less attention has been paid to movement disorders following abrupt clozapine withdrawal. This report describes 4 subjects who experienced severe dystonias and dyskinesias upon abrupt clozapine withdrawal. Method: Current and past medical records of 4 subjects with DSM-IV schizophrenia or schizoaffective disorder were reviewed. Results: All subjects had a history of neuroleptic-induced extrapyramidal symptoms, 1 had a history of severe dystonias, and 1 had neuroleptic malignant syndrome. All had mild orolingual tar dive dyskinesia prior to clozapine treatment. All subjects had received clozapine for several months, and 3 of the 4 subjects stopped clozapine abruptly. Two subjects experienced cholinergic rebound symptoms within hours, which resolved quickly. These subjects had severe limb-axial and neck dystonias and dyskinesias 5 to 14 days after clozapine withdrawal. Two subjects were unable to ambulate, and 1 had a lurching gait. Two gagged while eating or drinking. Two subjects were returned to clozapine, 1 was started on low-dose risperidone treatment, and 1 was started on olanzapine treatment. All experienced significant improvements in their mental state and movement disorders. Conclusion: Severe movement disorders, which may be worse than the movements prior to clozapine treatment, and cholinergic rebound symptoms may occur upon abrupt clozapine withdrawal and must be recognized in addition to the severe psychotic decompensation noted in some patients. Patients, families, and caregivers must be alerted to this possibility. Where possible, a slow clozapine taper, the use of anticholinergic agents, and symptomatic treatment may help minimize these withdrawal symptoms, and reintroduction of clozapine or treatment with the newer atypical agents can help in the clinical management of these symptoms.
引用
收藏
页码:472 / 477
页数:6
相关论文
共 47 条
[1]  
ABUZZAHAB FS, 1994, 33 ANN M AM COLL NEU, P225
[2]  
ALPHS LD, 1991, J CLIN PSYCHIAT, V52, P346
[3]  
BALDESSARINI RJ, 1995, ARCH GEN PSYCHIAT, V52, P1071
[4]  
BALDESSARINI RJ, 1995, ARCH GEN PSYCHIAT, V52, P189
[5]  
BLACK B, 1992, J CLIN PSYCHIAT, V53, P327
[6]   Severe extrapyramidal side effects when discontinuing clozapine and starting haloperidol [J].
Bobba, R ;
Carr, A .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1997, 42 (05) :530-530
[7]  
BORRISON RL, 1988, PSYCHOPHARMACOL B, V24, P262
[8]  
BOYSON SJ, 1988, J PHARMACOL EXP THER, V244, P987
[9]   WITHDRAWAL FROM NEUROLEPTIC DRUGS [J].
BROOKS, GW .
AMERICAN JOURNAL OF PSYCHIATRY, 1959, 115 (10) :931-932
[10]  
BRUDMAN C, 1991, AM J PSYCHIAT, V148, P1403